COMPUESTOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS ASOCIADOS CON BRAF

Se adjunta resumen de la invención Provided herein are compounds of the Formula I:and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associ...

Full description

Saved in:
Bibliographic Details
Main Authors COOK, Adam W, LAIRD, Ellen, TARLTON, Eugene, MORENO, David A, BARBOUR, Patrick, BROWN, Katie Keaton, PRIGARO, Brett Joseph, PAJK, Spencer Phillip, NEWHOUSE, Bradley Jon, HICKEN, Erik James, REN, Li, METCALF, Andrew T, KAHN, Dean Russell
Format Patent
LanguageSpanish
Published 31.01.2022
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Se adjunta resumen de la invención Provided herein are compounds of the Formula I:and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
Bibliography:Application Number: EC2020DI2193541